Nat Commun:改善伤口愈合的新靶点

2017-05-21 sunshine2015 来宝网

MicroRNA是新的治疗剂的有趣靶标结构。它们可以通过合成抗氧化剂阻断。然而,到目前为止,仅在局部使用这些数据是不可能的。歌德大学法兰克福的研究人员现在已经成功地实现了这一点,在光诱导型抗生素的帮助下治疗伤口愈合受损。



MicroRNA是新的治疗剂的有趣靶标结构。它们可以通过合成抗氧化剂阻断。然而,到目前为止,仅在局部使用这些数据是不可能的。歌德大学法兰克福的研究人员现在已经成功地实现了这一点,在光诱导型抗生素的帮助下治疗伤口愈合受损

MicroRNA是在细胞中键合到靶结构上的小基因片段,以这种方式防止某些蛋白质形成。由于它们在各种疾病的发生和表现中发挥关键作用,所以研究人员已经开发出所谓的阻止microRNA功能的抗体。然而,这种方法的缺点是可能导致整个身体的副作用,因为microRNA可以在各种器官中执行不同的功能。歌德大学法兰克福的研究人员现在已经解决了这个问题。

由德国法兰克福大分子复合物卓越研究组织的Alex Heckel教授和Stefanie Dimmeler教授领导的研究小组开发了可以通过使用特定波长的光在有限的局部区域内非常有效地激活的抗氧化物质。为此,将抗氧化剂锁定在光敏分子笼中,一旦用特定波长的光照射就会分解。

作为测试这些新型抗菌药物治疗效果的手段,研究人员选择了microRNA-92a作为目标结构。这种情况经常出现在患有慢性创伤的糖尿病患者身上。他们将光敏笼中的抗体注入小鼠的皮肤,然后借助于光将治疗剂释放到组织中。这些研究小组一起证明了对microRNA-92a的有效激活能帮助伤口愈合

“我们的数据也证实了这些发现,首次通过使用抗疟剂阻断microRNA-92a可以改善伤口愈合,我们的数据也证实了microRNA-92a功能的确只有局部抑制,其他器官如肝脏。”Stefanie Dimmeler教授强调了试验的临床意义。

研究人员现在想看看他们是否也可以扩大使用光诱导型抗生素治疗其他疾病。特别是他们想检查有毒的抗生素是否也可以局部攻击肿瘤。

原始出处:

Tina Lucas, Florian Schafer, Patricia Müller, et al. Light-inducible antimiR-92a as a therapeutic strategy to promote skin repair in healing-impaired diabetic mice, Nature Communications (2017). DOI: 10.1038/ncomms15162

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1882064, encodeId=5d1d188206482, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 01 02:06:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087036, encodeId=34f0208e036a8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 06 20:06:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288213, encodeId=32a71288213b0, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue May 23 13:06:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309855, encodeId=0648130985597, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 23 13:06:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201335, encodeId=e2dc201335ce, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon May 22 21:55:17 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
    2017-12-01 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1882064, encodeId=5d1d188206482, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 01 02:06:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087036, encodeId=34f0208e036a8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 06 20:06:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288213, encodeId=32a71288213b0, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue May 23 13:06:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309855, encodeId=0648130985597, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 23 13:06:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201335, encodeId=e2dc201335ce, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon May 22 21:55:17 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
    2017-12-06 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1882064, encodeId=5d1d188206482, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 01 02:06:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087036, encodeId=34f0208e036a8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 06 20:06:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288213, encodeId=32a71288213b0, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue May 23 13:06:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309855, encodeId=0648130985597, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 23 13:06:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201335, encodeId=e2dc201335ce, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon May 22 21:55:17 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
    2017-05-23 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1882064, encodeId=5d1d188206482, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 01 02:06:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087036, encodeId=34f0208e036a8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 06 20:06:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288213, encodeId=32a71288213b0, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue May 23 13:06:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309855, encodeId=0648130985597, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 23 13:06:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201335, encodeId=e2dc201335ce, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon May 22 21:55:17 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1882064, encodeId=5d1d188206482, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 01 02:06:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087036, encodeId=34f0208e036a8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 06 20:06:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288213, encodeId=32a71288213b0, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue May 23 13:06:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309855, encodeId=0648130985597, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue May 23 13:06:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201335, encodeId=e2dc201335ce, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon May 22 21:55:17 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
    2017-05-22 Y—xianghai

    学习了。

    0

相关资讯

Stem Cells:沉默microRNA促进间充质干细胞进行关节软骨损伤修复

最近来自意大利的科学家们在国际学术期刊Stem Cells上发表了一项最新研究进展,他们发现在人类间充质干细胞中沉默一种抗软骨形成的microRNA能够促进间充质干细胞向软骨细胞方向分化,为应用间充质干细胞进行体内软骨组织修复提供了新的可能。随着间充质干细胞在临床应用原来越为广泛,对借助组织工程技术利用人类间充质干细胞进行有效的关节软骨修复的需求越来越大。但是想要利用hMSC实现对软骨的修复,如何

Science:特殊MicroRNA分子的缺失或在神经变性疾病中扮演重要角色

最近,来自索尔克研究所的科学家通过研究在国际杂志Science上发表文章称,人类机体的特殊DNA可以产生一种分子,该分子对于控制机体的肌肉有着重要的影响作用;研究者发现,不能够产生microRNAs的动物或许会引发破坏性的神经变性疾病症状,比如肌萎缩性侧索硬化等疾病,本文研究阐明了microRNAs在神经系统中的关键角色,并为开发治疗神经变性疾病的新型疗法提供了新的思路。 研究者Samuel

Nature:脂肪会通过释放microRNA调节你的身体

美国Joslin糖尿病中心的科学家鉴定出脂肪也会递送microRNA来调节其它器官。这篇文章2月15日在线发表在Nature上。这个机制提供了一个开发全新治疗方法的可能:运用脂肪细胞开发基因疗法来治疗代谢性疾病、癌症和肝脏或其它器官别的状况。

JBC:利用食物传递microRNA治疗疾病可能并不现实

近几年关于外源microRNA是否能够从食物中吸收以及是否具有生理学作用的问题一直存在争议。最近一项研究利用小鼠模型给出了答案,这项研究发现通过饮食吸收microRNA的假设并不会发生,而这项研究的发表也对基于microRNA制做功能性食品进行疾病治疗的概念提出了质疑。  之前有研究表明在食物消化过程中,microRNA会进入人体调节人体生理学过程,如果这些研究结果是真的,那么将mic

Nat med:GWAS分析找到调节胆固醇和脂代谢的microRNA

                                最近,在一项发表在国际学术期刊Nature Medicine上的研究中,来自美国麻省总医院的研究人员新发现四个microRNA在胆固醇和甘油三酯代谢过程中发挥重要调节作用

JEM:揭示microRNA分子在炎性肠病发病过程中的关键角色

近日,一项刊登在国际杂志The Journal of Experimental Medicine上的一篇题为“Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome”的研究报告中,来自国外的研究人员